For the Inventor, By the Inventor

Enter assignee name

Zora Biosciences Oy

USPTO Granted Patents = 26

% Expired Patents = 11.5

CIPO Patents = 1

EPO Patents = 10

Forward Citations = 18

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Reijo Laaksonen (25 out of 25 patents)

Reini Hurme (18 out of 18 patents)

Kim Ekroos (17 out of 17 patents)

4. Riikka Katainen (15 out of 15 patents)

5. Kirill Tarasov (5 out of 5 patents)

6. Minna Jänis (5 out of 5 patents)

7. Mika Hilvo (4 out of 4 patents)

8. Riika Katainen (2 out of 2 patents)

9. Virve Vaeisaenen (1 out of 1 patent)

10. Matej Oresic (1 out of 3 patents)

11. Terho Lehtimäki (1 out of 1 patent)

12. Hannu Päivä (1 out of 1 patent)

13. Jonathan Shaw (1 out of 1 patent)

14. Dianna Magliano (1 out of 1 patent)

15. Kevin Huynh (1 out of 1 patent)

Core Competencies:

Biomarkers

Cardiovascular Disease

Lipidomic

Ceramides

Diabetes Detection

Ovarian Cancer

Atherosclerosis

Coronary Artery Disease

Statin Treatment

Muscle Toxicity

Prediction Methods

Diagnostic Method

26 patents: Sort by Forward Citations

1. 12399188 - Biomarkers for cardiovascular events (2025-08-26),

2. 12313634 - Methods for prediction and early detection of diabetes (2025-05-27),

3. 12270816 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2025-04-08),

4. 12025623 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2024-07-02),

5. 11940453 - Ceramides and their use in diagnosing CVD (2024-03-26),

6. 11474116 - Ceramides and their use in diagnosing CVD (2022-10-18),

7. 10955427 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2021-03-23),

8. 10551394 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2020-02-04),

9. 10534001 - Methods for detecting ovarian cancer (2020-01-14),

10. 10261101 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2019-04-16),

11. 10197582 - Ceramides and their use in diagnosing CVD (2019-02-05),

12. 10184932 - Use of ceramides and LPLs in diagnosing CVD (2019-01-22),

13. 9863965 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment (2018-01-09),

14. 9857386 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2018-01-02),

15. 9841431 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2017-12-12),

Company Overview

Zora Biosciences Oy, based in Espoo, Finland, specializes in the development of innovative solutions in the field of biotechnology. The company focuses on harnessing advanced technologies to create products that enhance health and well-being. With a commitment to research and development, Zora Biosciences is dedicated to addressing complex challenges in life sciences, aiming to contribute to the advancement of medical and therapeutic applications. Their expertise spans various domains, positioning them as a key player in the biotech landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

26 Patents

#29 in Espoo

#137 in Finland

#24,826 in the World

Zora Biosciences Oy

Forward Citations = 18

16 inventors:

Reijo Laaksonen (25 out of 25 patents)

Reini Hurme (18 out of 18 patents)

Kim Ekroos (17 out of 17 patents)

4. Riikka Katainen (15 out of 15 patents)

5. Kirill Tarasov (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zora Biosciences Oy. Retrieved from https://idiyas.com/company/zora-biosciences-oy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…